Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
GlycoMimetics (GLYC) Stock Price & Analysis
731 Followers
GLYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $4.16
Previous Close$1.85
Volume213.95K
Average Volume (3M)396.18K
Market Cap
$118.85M
Enterprise Value$54.50M
Total Cash (Recent Filing)$65.00M
Total Debt (Recent Filing)$651.73K
Price to Earnings (P/E)-2.4
Beta2.07
Next Earnings
Aug 03, 2023EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding64,245,674
10 Day Avg. Volume499,352
30 Day Avg. Volume396,181
Standard Deviation0.34
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue726.72
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$8.00Price Target Upside332.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
GlycoMimetics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLYC FAQ
What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.51 and its highest was $4.16 in the past 12 months.
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is Aug 03, 2023 which is in 68 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on May 03, 2023. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Undervalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate is -$0.18.
How many shares outstanding does GlycoMimetics have?
GlycoMimetics has 64,245,674 shares outstanding.
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went down -3.546%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in GLYC
---
GlycoMimetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (332.43% Upside)
$8.00 (332.43% Upside)
Blogger Sentiment
Bullish
GLYC Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $230.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
208.33%
12-Months-Change
Fundamentals
Return on Equity
-65.12%
Trailing 12-Months
Asset Growth
-15.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
Top 5 ETFs holding GLYC
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold GLYC. The ETFs are listed according to market value of GLYC within the ETF
---
CytomX Therapeutics
―
Alzamend Neuro
―
Senti Biosciences
―
Olema Pharmaceuticals
―
Candel Therapeutics
―
---